Skip to main
HSCS

HSCS Stock Forecast & Price Target

HSCS Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

HeartSciences Inc. is demonstrating a positive outlook with an upward revision of its FY26 EPS estimates, reflecting a decrease in projected losses from $(8.63) to $(4.17), indicating improved financial performance expectations. The anticipated FDA approval of the MyoVista device and the ongoing rollout of the MyoVista Insights cloud platform position the company for significant market expansion in cardiac diagnostics. Moreover, the company's new price target of $9.20, derived from a Net Present Value analysis, suggests considerable upside potential, supported by the increasing recognition of AI technology in transforming ECG diagnostics for improved early heart disease detection.

Bears say

HeartSciences Inc. faces significant challenges that contribute to a negative outlook on its stock, particularly due to a substantial reduction in projected revenues, with FY2026 estimates revised from $1.2 million to $0.1 million primarily due to FDA-related delays. Additionally, the company is exposed to numerous risks including potential liquidity issues, the need for successful clinical trial outcomes, regulatory approval hurdles, and commercialization difficulties, all of which could adversely affect its operations. The overall environment is further complicated by competition and fluctuating investor sentiment towards healthcare stocks, undermining confidence in the company’s ability to achieve its objectives.

HSCS has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Heart Test Laboratories Inc (HSCS) Forecast

Analysts have given HSCS a Strong Buy based on their latest research and market trends.

According to 1 analysts, HSCS has a Strong Buy consensus rating as of Jan 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Heart Test Laboratories Inc (HSCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.